臨牀透析 Vol.18 No.5(1-5)


特集名 透析と嚢胞性腎疾患
題名 常染色体優性多発性嚢胞腎 (5) 透析療法
発刊年月 2002年 05月
著者 荒井 純子 東京女子医科大学腎臓病総合医療センター内科
【 要旨 】 2000年12月現在のわが国の慢性透析患者総数は201,914名で，そのうちの嚢胞腎透析患者数は6,404名で全体の3.2％にあたる．嚢胞腎透析患者の95％は血液透析(hemodialysis;HD)をうけているが透析導入後の予後は，比較的良好で10年生存率は56.9％である．とくに常染色体優性多発性嚢胞腎(ADPKD)患者に特有な合併症に対する治療は予後に大きく影響を与えるため，今後もこれらに関して多施設間での共同研究が重要となる．また，症例によっては腎移植を考慮する．
Theme Dialysis and Cystic Renal Disease
Title Polycystic kidney disease -- treatment with dialysis
Author Junko Arai Department of Medicine, Kidney Center, Tokyo Women's Medical University
[ Summary ] Autosomal dominant polycystic kidney disease is the most common renal cystic disease which causes end stage renal disease in adults. In Japan, PKD accounted for 3.2% of patients on maintenance hemodialysis at the end of 2000. The prognosis for polycystic kidney disease during endstage renal disease (ESRD) treatment is good, compared to that for other causes of ESRD. The ten year survival rate is 56.9% for those on hemodialysis. Specific complications related to ADPKD may expected to compromise survival and outcome of patients treated with maintenance hemodialysis. Longer term prognoses remain to be examined in a more extended, case-controlled cohort and transplantation should be considered for some patients.
戻る